Prolonged administration of bisphosphonates is well-tolerated and effective for skeletal-related events in Chinese breast cancer patients with bone metastasis

Breast

Volumn 21, Issue 4, 2012, Pages 544-549

  Ding, Xiaoyan ^a   Fan, Ying ^a   Ma, Fei ^a   Li, Qing ^a   Wang, Jiayu ^a   Zhang, Pin ^a   Yuan, Peng ^a   Xu, Binghe ^a  

^a CANCER HOSPITAL   (China)

Author keywords

Bisphosphonates; BM; Bone metastasis; BPs; BrCa; Breast cancer; Efficacy; ONJ; Safety; Skeletal related events; SMR; SRE

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; ARTICLE; BONE DISEASE; BONE METASTASIS; BREAST CANCER; CALCIUM BLOOD LEVEL; CHINESE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPOCALCEMIA; INCIDENCE; IRRADIATION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; NEPHROTOXICITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; SKELETAL RELATED EVENT; TREATMENT DURATION;

EID: 84863883435     PISSN: 09609776     EISSN: 15323080     Source Type: Journal    
DOI: 10.1016/j.breast.2012.04.008     Document Type: Article

References (30)

1. Manders K., van de Poll-Franse L.V., Creemers G.J., Vreugdenhil G., van der Sangen M.J., Nieuwenhuijzen G.A., et al. Clinical management of women with metastatic breast cancer: a descriptive study according to age group. BMC Cancer 2006, 6:179.
2. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
3. Hatoum H.T., Lin S.J., Smith M.R., Barghout V., Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases: analysis of a national medical claims database. Cancer 2008, 113:1438-1445.
4. Heras P., Kritikos K., Hatzopoulos A., Georgopoulou A.P. Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer. Eur J Cancer Care (Engl) 2009, 18:653-656.
5. Machado M., Cruz L.S., Tannus G., Fonseca M. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials. Clin Ther 2009, 31:962-979.
6. Carteni G., Bordonaro R., Giotta F., Hong A., Mansi J., Dodwell D., et al. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial. Oncologist 2006, 11:841-848.
7. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000, 88:1082-1090.
8. Jensen A.O., Jacobsen J.B., Norgaard M., Yong M., Fryzek J.P., Sørensen H.T. Incidence of bone metastases and skeletal-related events in breast cancer patients: a population-based cohort study in Denmark. BMC Cancer 2011, 11:29.
9. Guarneri V., Donati S., Nicolini M., Giovannelli S., D'Amico R., Conte P.F. Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years. Oncologist 2005, 10:842-848.
10. Pecherstorfer M., Rivkin S., Body J.J., Diel I., Bergström B. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006, 26:315-322.
11. Dincer M., Altundag K., Harputluoglu H., Aksoy S., Cengiz M., Gullu I. Renal safety of zoledronic acid administration beyond 24 months in breast cancer patients with bone metastases. Med Oncol 2008, 25:356-359.
12. Ali S.M., Esteva F.J., Hortobagyi G., Harvey H., Seaman J., Knight R., et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001, 19:3434-3437.
13. Walter C., Al-Nawas B., du Bois A., Buch L., Harter P., Grötz K.A. Incidence of bisphosphonate-associated osteonecrosis of the jaws in breast cancer patients. Cancer 2009, 115:1631-1637.
14. Migliorati C.A., Epstein J.B., Abt E., Berenson J.R. Osteonecrosis of the jaw and bisphosphonates in cancer: a narrative review. Nat Rev Endocrinol 2011, 7:34-42.
15. Cancer Therapy Evaluation Program Common terminology criteria for adverse events (CTCAE). Version 3.0 August9, 2006, DCTD, NCI, NIH, DHHS, [accessed 16.7.2007]. http://ctep.cancer.gov/forms/CTCAEv3.pdf.
16. Cockcroft D.W., Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 1976, 16:31-34.
17. Burr D.B. ASBMR Task Force. Summary of ASBMR Task Force on ONJ. J Musculoskelet Neuronal Interact 2007, 7:354-355.
18. Lipton A. Efficacy and safety of intravenous bisphosphonates in patients with bone metastases caused by metastatic breast cancer. Clin Breast Cancer 2007, 7(Suppl 1):S14-S20.
19. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003, 98:1735-1744.
20. Gordon D.H. Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer 2005, 6:125-131.
21. Henk H.J., Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ 2011 Nov 8, [Epub ahead of print] PubMed PMID: 22017235.
22. Yamashita J., McCauley L.K., Van Poznak C. Updates on osteonecrosis of the jaw. Curr Opin Support Palliat Care 2010, 4:200-206.
23. Migliorati C.A., Siegel M.A., Elting L.S. Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment. Lancet Oncol 2006, 7:508-514.
24. Ripamonti C.I., Maniezzo M., Campa T., Fagnoni E., Brunelli C., Saibene G., et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 2009, 20:137-145.
25. Christodoulou C., Pervena A., Klouvas G., Galani E., Falagas M.E., Tsakalos G., et al. Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 2009, 76:209-211.
26. McLachlan S.A., Cameron D., Murray R., Tripathy D., Bergström B. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006, 26:43-48.
27. Vander Walde A., Hurria A. Aging and osteoporosis in breast and prostate cancer. CA Cancer J Clin 2011, 61:139-156.
28. Brown J.E., Cook R.J., Lipton A., Costa L., Coleman R.E. Prognostic factors for skeletal complications from metastatic bone disease in breast cancer. Breast Cancer Res Treat 2010, 123:767-779.
29. Koizumi M., Yoshimoto M., Kasumi F., Iwase T., Ogata E. Post-operative breast cancer patients diagnosed with skeletal metastasis without bone pain had fewer skeletal-related events and deaths than those with bone pain. BMC Cancer 2010, 10:423.
30. Clézardin P. Potential anticancer properties of bisphosphonates: insights from preclinical studies. Anticancer Agents Med Chem 2011 Aug 17, [Epub ahead of print] PubMed PMID: 21864232.